异位性皮肤炎药物市场－全球产业规模、份额、趋势、机会和预测，按药物类别、给药途径、地区和竞争格局划分，2020-2030年预测

2024年全球异位性皮肤炎药物市场规模为145.2亿美元，预计到2030年将以8.83%的复合年增长率增长至241.2亿美元。全球异位性皮肤炎药物市场涵盖用于治疗异位性皮肤炎的药物，异位性皮肤炎是一种以剧烈搔痒和湿疹样皮损为特征的慢性发炎性皮肤病。推动市场扩张的关键因素包括：该疾病在全球范围内的患病率不断上升；对疾病病理生理学认识的显着进步促成了新型标靶疗法的开发；以及诊断能力的提高有助于更早启动治疗。

主要市场驱动因素

主要市场挑战

主要市场趋势

个人化医疗和生物标记指导疗法

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球异位性皮肤炎药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（生物製剂、PDE4抑制剂、皮质类固醇、钙调神经磷酸酶抑制剂）
  • 依给药途径（外用、注射、口服）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美异位性皮肤炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲异位性皮肤炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区异位性皮肤炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲异位性皮肤炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲异位性皮肤炎药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球异位性皮肤炎药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Abbvie, Inc.
• Bausch Health Companies Inc.
• Nestle India Limited
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Evelo Biosciences, Inc.
• Cara Therapeutics Inc.
• Bristol-Myers Squibb Company

第十六章：策略建议

第17章调查会社について・免责事项

The Global Atopic Dermatitis Drugs Market, valued at USD 14.52 Billion in 2024, is projected to experience a CAGR of 8.83% to reach USD 24.12 Billion by 2030. The global atopic dermatitis drugs market comprises pharmaceutical interventions designed to manage atopic dermatitis, a chronic inflammatory skin condition characterized by intense pruritus and eczematous lesions. Key drivers supporting market expansion include the increasing global prevalence of the disease, significant advancements in understanding disease pathophysiology leading to the development of novel targeted therapies, and improved diagnostic capabilities facilitating earlier treatment initiation.

Key Market Drivers

The increasing global prevalence of atopic dermatitis profoundly influences the pharmaceutical market by continually expanding the patient population requiring advanced therapeutic solutions. This chronic inflammatory skin condition manifests across all demographics, generating persistent demand for effective drug interventions capable of managing diverse disease severities. The expanding patient pool necessitates a broader portfolio of medications to alleviate symptoms and address underlying immunological dysregulation.

Key Market Challenges

The high cost associated with advanced therapeutic agents, particularly biologics and Janus kinase inhibitors, significantly impedes the growth of the global atopic dermatitis drugs market. These substantial expenses create considerable reimbursement hurdles for healthcare systems and often result in restricted patient access to these critical medications. This limitation directly slows market expansion by preventing a broader patient population from initiating or continuing effective advanced treatments, despite clinical need. The financial burden impacts both individual patients, who may face high out-of-pocket costs, and payers, who implement stringent coverage criteria.

Key Market Trends

Personalized Medicine and Biomarker-Guided Therapies

This trend fundamentally reshapes the global atopic dermatitis drugs market by fostering treatments tailored to individual patient profiles. Leveraging biomarkers and genetic insights, this precision approach aims to enhance therapeutic efficacy and minimize adverse reactions, optimizing patient outcomes. The Canadian Dermatology Foundation, in 2025, supported this direction by offering Innovation Grants of up to $100,000 over two years for dermatology research projects. Furthermore, Eli Lilly announced in March 2024 results from a lebrikizumab study specifically for people with skin of color and moderate-to-severe atopic dermatitis, evaluating 50 patients with darker skin tones. This signifies the market's evolution towards precise, demographic-specific therapeutic solutions.

Key Market Players

• Abbvie, Inc.
• Bausch Health Companies Inc.
• Nestle India Limited
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Evelo Biosciences, Inc.
• Cara Therapeutics Inc.
• Bristol-Myers Squibb Company

Report Scope:

In this report, the Global Atopic Dermatitis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atopic Dermatitis Drugs Market, By Drug Class:

• Biologics
• PDE4 Inhibitors
• Corticosteroids
• Calcineurin Inhibitors

Atopic Dermatitis Drugs Market, By Route of Administration:

• Topical
• Injectable
• Oral

Atopic Dermatitis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Atopic Dermatitis Drugs Market.

Available Customizations:

Global Atopic Dermatitis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atopic Dermatitis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Biologics, PDE4 Inhibitors, Corticosteroids, Calcineurin Inhibitors)
  • 5.2.2. By Route of Administration (Topical, Injectable, Oral)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Atopic Dermatitis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atopic Dermatitis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
  • 6.3.2. Canada Atopic Dermatitis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
  • 6.3.3. Mexico Atopic Dermatitis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration

7. Europe Atopic Dermatitis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atopic Dermatitis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
  • 7.3.2. France Atopic Dermatitis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
  • 7.3.3. United Kingdom Atopic Dermatitis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
  • 7.3.4. Italy Atopic Dermatitis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
  • 7.3.5. Spain Atopic Dermatitis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Atopic Dermatitis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Atopic Dermatitis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
  • 8.3.2. India Atopic Dermatitis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
  • 8.3.3. Japan Atopic Dermatitis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
  • 8.3.4. South Korea Atopic Dermatitis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
  • 8.3.5. Australia Atopic Dermatitis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration

9. Middle East & Africa Atopic Dermatitis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Atopic Dermatitis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
  • 9.3.2. UAE Atopic Dermatitis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
  • 9.3.3. South Africa Atopic Dermatitis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration

10. South America Atopic Dermatitis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Atopic Dermatitis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
  • 10.3.2. Colombia Atopic Dermatitis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
  • 10.3.3. Argentina Atopic Dermatitis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Atopic Dermatitis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbvie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bausch Health Companies Inc.
• 15.3. Nestle India Limited
• 15.4. Pfizer Inc.
• 15.5. Regeneron Pharmaceuticals Inc.
• 15.6. Evelo Biosciences, Inc.
• 15.7. Cara Therapeutics Inc.
• 15.8. Bristol-Myers Squibb Company

16. Strategic Recommendations

17. About Us & Disclaimer